NewcelX raises $1.35 million in equity financing at 30% premium

NewcelX Ltd. (NASDAQ: NCEL) announced it has entered into securities purchase agreements for a private placement priced at $2.75 per share, representing a 30% premium to the company's closing price on March 31, 2026.

The clinical-stage biopharmaceutical company is selling 490,907 common shares and common share equivalents, along with warrants to purchase 687,270 additional shares at $3.025 per share. The offering includes participation from existing shareholders and is expected to close around April 15, 2026, subject to customary closing conditions.

NewcelX plans to use the net proceeds, combined with a previously announced $25 million equity line, to advance its lead Type 1 diabetes program NCEL-101, developed in collaboration with Eledon Pharmaceuticals. The funds will also support other development programs, working capital and general corporate purposes.

"We are very pleased to secure funding at a 30% premium to market, especially in today's challenging biotech environment," said Ronen Twito, Executive Chairman and CEO of NewcelX. "We believe the strong participation from our existing investors further reinforces our conviction in the strategy and in the potential of NCEL-101 to address the significant unmet need in Type 1 Diabetes."

The securities are being issued through a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under federal securities laws. NewcelX develops stem cell-based therapies for Type 1 diabetes, with its lead program NCEL-101 designed to restore functional insulin production through cell replacement therapy.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Bimegren Energy (BESS) files $100M mixed shelf
• RiverNorth Opportunities Fund raises $35.2M in rights offering